The aryl hydrocarbon receptor (AhR) is a transcription factor that mediates the inhibitory effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on prostate growth and also modulates normal prostate development. This is evidenced by AhR null mice (Ahr À/À ) having smaller dorsolateral and anterior prostates, even though all prostate lobes remain histologically normal. To test the hypothesis that loss of the AhR increases the rate of prostate carcinogenesis, the incidence of macroscopic prostate tumors was determined in Ahr +/+ , Ahr +/À and Ahr À/À C57BL/6J transgenic adenocarcinoma of the mouse prostate (TRAMP) mice at 35, 70, 105, 140, 175 and 210 days of age. From 140 days, prostate tumor incidence was greater in Ahr À/À (60%) and Ahr +/À (43%) mice than in Ahr +/+ mice (16%). Allele quantification did not indicate a loss of the wild-type Ahr allele in heterozygous TRAMP tumors, suggesting that tumor formation in these mice was not due to a loss of Ahr heterozygosity. Prostatic SV40 large T antigen mRNA expression and protein localization were comparable in TRAMP mice of each Ahr genotype. Prostates from all mice of each Ahr genotype were histologically indistinguishable, exhibiting diffuse epithelial hyperplasia by 105 days of age. mRNA expression and protein localization for molecular markers of neuroendocrine differentiation, including chromogranin A and neuropilin-1, were elevated in prostate tumors compared to tumor-free ventral prostates, regardless of Ahr genotype or age. Taken together, these results demonstrate that the Ahr inhibits prostate carcinogenesis in C57BL/6J TRAMP mice by interfering with neuroendocrine differentiation.
Introduction
Male reproductive tract development is disrupted by in utero and lactational exposure to the aryl hydrocarbon receptor (AhR) agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD; 1,2). Ventral, dorsolateral and anterior prostate development in the mouse is inhibited in a lobe-dependent manner by in utero and lactational TCDD exposure (3) (4) (5) (6) (7) (8) . This response results from lobe-specific inhibition of both prenatal epithelial bud formation from the prostate anlage, the urogenital sinus (9) and postnatal ductal branching morphogenesis (8) .
TCDD binds to the AhR, a basic helix-loop-helix/PerArnt-Sim ligand-activated transcription factor that is bound in the cytoplasm to two 90 kDa heat-shock proteins (HSP) and one AhR interacting protein (10, 11) . The ligand/AhR complex translocates to the nucleus where the chaperone proteins dissociate and the ligand-bound AhR dimerizes with the AhR nuclear translocator (ARNT) to enhance transcription of genes containing dioxin response elements. AhR and ARNT proteins have been identified in ventral and dorsolateral lobes of the rat prostate, and cytochrome P4501A1 is induced in both lobes in response to TCDD exposure (12) .
The availability of mice lacking the AhR (Ahr À/À ) has permitted AhR-mediated effects of TCDD to be identified and the role of the AhR in normal development to be determined (13) (14) (15) . In AhR null mice, reduction in ventral, dorsolateral and anterior prostate weights caused by in utero and lactational TCDD exposure were AhR-dependent (6) . Dorsolateral and anterior prostate weights in untreated AhR null mice were reduced compared with their wild-type littermates at various ages, suggesting that the AhR, in the absence of TCDD, is involved in normal development of these two prostate lobes. Serum testosterone concentrations were not altered in AhR null mice, and slight reductions in serum 5a-androstane-3a,17b-diol concentrations were unlikely responsible for the reduced dorsolateral and anterior prostate weights (6) . Furthermore, prostate histology, androgen receptor (AR) mRNA levels, and androgen-dependent gene expression were not altered in AhR null mice, suggesting adequate androgen action (6) . Impaired growth of the developing prostate by TCDD activation of AhR, or by absence of AhR from AhR null mice, raised the possibility that the AhR may regulate prostate carcinogenesis later, particularly if 'reawakening' of early prostate growth regulatory signals is involved (16) .
There have been a limited number of investigations on the potential role of AhR signaling in prostate cancer. Western blot analysis identified the AhR in epithelial and stromal cells of human fetal, benign hyperplastic and malignant prostate (17) , suggesting that this organ could be a target of a TCDD response in men. Recent studies have demonstrated that Vietnam veterans exposed to TCDD-contaminated Agent Orange had a greater risk of developing prostate cancer (18) , although some earlier studies failed to identify an association between TCDD exposure and prostate cancer risk (19) . Recently, we found that in utero and lactational TCDD exposure increases the incidence of pre-cancerous prostatic lesions in senescent C57BL/6J mice, a mouse strain not naturally susceptible to prostate cancer (20) . Such results raise the possibility that AhR activation by TCDD may increase prostate cancer risk, particularly in humans and animal models susceptible to prostate carcinogenesis.
However, the role of AhR in prostate carcinogenesis in the absence of exogenous ligand remains to be determined.
Development of prostate cancer in the TRAMP model provides an opportunity to investigate effects of Ahr genotype on distinct stages of mouse prostate carcinogenesis (21) (22) (23) (24) (25) . The TRAMP model utilizes the rat probasin gene promoter to drive expression of simian virus 40 (SV40) large T and small t antigens. Transgene expression under control of the androgen-dependent probasin promoter is specific to prostatic epithelium and is hormonally and developmentally regulated. TRAMP mice express the T antigen oncoprotein by 8 weeks of age and develop distinct pathology in the prostate epithelium by 10 weeks of age. Advanced stages of tumor development are characteristically AR-negative and have greater localization for markers of neuroendocrine tumors (24) .
In the present study, we investigate the effect of Ahr genotype on prostate carcinogenesis in TRAMP mice. We report that prostate tumors develop with greater frequency in TRAMP mice lacking both (Ahr À/À ) or one (Ahr
) Ahr allele compared with wild-type mice (Ahr
. Furthermore, we demonstrate that the tumors present in TRAMP mice of each Ahr genotype have evidence of a neuroendocrine phenotype, regardless of the age they first appear. These findings suggest that the Ahr inhibits onset of neuroendocrine prostate tumors in a gene-dosage-dependent manner in the TRAMP model. (26) . TRAMP genotyping measured transgene DNA by quantitative real-time LightCycler (Roche Molecular Biochemicals, Indianapolis, IN) PCR using primers described previously (21) and cytokeratin 8 primers as the loading control (6).
Materials and methods

Transgenic mice
Tissue preparation and histology TRAMP mice of each Ahr genotype were necropsied at 35, 70, 105, 140, 175 and 210 days of age to determine the incidence of macroscopic prostate tumors. Where tumor burden required euthanasia prior to scheduled termination, mice were included in the predetermined age group for analysis. A macroscopic tumor was characterized as any mass visible at the time of necropsy, and confirmed using a dissecting microscope, if necessary. To minimize genetic diversity, littermates of each Ahr genotype were necropsied at different ages. All prostate lobes and prostate tumors were removed and weighed. One lobe of the dorsolateral and ventral prostate or one-half of a bisected prostate tumor was frozen in liquid nitrogen for RT-PCR evaluation of gene expression. The other dorsolateral and ventral lobe or the other half of the bisected prostate tumor was fixed overnight in Bouin's, paraffinembedded, sectioned (5 mm), and processed for histological analysis by light microscopy according to criteria previously described (27) .
Quantification of wild-type Ahr allele in heterozygous TRAMP prostate tumors To determine if tumors in heterozygous TRAMP mice were due to loss of heterozygosity, specifically resulting from loss of the wild-type Ahr allele, prostate tumors from Ahr +/+ , Ahr +/À and Ahr À/À mice were processed as previously described for ear punch samples (26) . Quantitative analysis of wild-type and knockout alleles was determined by real-time LightCycler PCR. PCR reactions (6) using Ahr (AGTAAAGCCCATCCCCGCTG and ATCAAAGAAGCTCTTGGCCC, respectively) and neomycin for Ahr null (TTGGGTGGAGAGGCTATTCG and AGGTGAGATGACAGGAGATC, respectively), primers were denatured at 94 C for 30 s, then amplified for 40 three-step cycles (94 C for 0 s hold melting, 65 C annealing for 5 s, and 72 C for 10 s extension). Double-stranded fluorescent product was detected at the end of each cycle and abundance of each allele was derived from the respective crossing point using LightCycler software. Product specificity was determined by comparison of melting curves, and the ratio of wild-type Ahr allele relative to Ahr null allele was calculated for each sample.
Immunohistochemistry
Large T antigen immunohistochemistry was carried out on deparaffinized and rehydrated tissue sections (5 mm). Boiling citric acid antigen retrieval preceded peroxide quenching of endogenous peroxidase activity. Mouse monoclonal SV40 large T antigen (Santa Cruz Biotechnology, Santa Cruz, CA) staining utilized the M.O.M. kit (Vector Laboratories, Burlingame, CA). Chromogranin A (Zymed, San Francisco, CA) non-specific binding was blocked with non-immunized goat serum. Horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (Vector Laboratories, Burlingame, CA) preceded streptavidin-peroxidase incubation (Dako). Primary antibodies were incubated overnight at 4 C in a humidity chamber, and color developed using NOVA-Red chromagen (Vector Laboratories). Slides were photographed using a Nikon D50 digital camera mounted on a Nikon Eclipse TE300 Microscope.
Real-time reverse transcription PCR mRNA quantification mRNA expression was determined for dorsolateral prostates, ventral prostates, and prostate tumors collected during the time-course study. Chromogranin A and neuropilin-1 mRNA identified neuroendocrine differentiation and SV40 T antigen mRNA was determined to quantify transgene expression. PCR reagents and conditions were carried out as described for Ahr allele quantification, utilizing cDNA (6) and the following primer pairs: cyclophilin: ATCACGGCCGATGACGAGCC, TCTCTCCGTAGATGGAC-CTGC; SV40 T antigen: AGAGCAGAATTGTGCAGTGG, TGGGACTGT-GAATCAATGCC; chromogranin A: TTCAAGGCCAGACTGCTGC, AAT-AGTCAGGAGTTCTCGGC; neuropilin-1: TGCTTTCACTGTAAGCTGGG, TGAAGTCAGTCACACTTGGTC, AR: AATCTGGATGTGGAGAGAGC, AGAGAACAGAACACTAGCGC. Serially-diluted standards of known concentrations (6) and unknown cDNA samples were amplified simultaneously using the same reaction mixture. mRNA abundance for each gene of interest was expressed relative to that of cyclophilin.
Western blot analysis
Frozen prostate or prostate tumors were homogenized in lysis buffer containing 0.1% Triton X-100 and protease inhibitors using a Tissumizer homogenizer (Tekmar, Cincinnati, OH). Protein concentrations were determined using the Pierce BCA kit (South San Francisco, CA). The extracts were boiled in sample buffer containing 10% b-mercaptoethanol and 10% SDS and 40 mg of protein from each sample was separated on SDS polyacrylamide gels. Proteins were transferred to a hybond membrane (Amersham Biosciences, Piscataway, NJ) on a semi-dry blotting unit (Fisher Scientific, Pittsburgh, PA). Non-specific antibody binding was blocked by 5% non-fat dry milk in TBST. Antibodies for AR (Santa Cruz Biotechnology, Inc, Santa Cruz, CA diluted 1:5000) and b-actin (Cell Signaling Technology, Beverly, MA) in TBST containing 3% non-fat dry milk were incubated overnight at 4 C. Membranes were washed with TBST prior to incubation with HRP-conjugated secondary antibody (Zymed, 1:1500) in blocking buffer. Membranes were washed with TBST, and bands detected using hyperfilm exposed to chemiluminescent substrate (Pierce). Band intensity was determined using ImageQuant TL software (Amersham Biosciences). AR protein levels were expressed relative to b-actin protein levels for each sample.
Statistical Analysis
Statistical analysis was conducted with the litter as the experimental unit. Analysis of variance (ANOVA) was conducted on parametric data that passed Levene's test for homogeneity of variance and were normally distributed. If a significant effect was found, the least significant difference test was used to determine which group(s) differed from the appropriate control group. Incidence data were analyzed by the row · column Chi-squared test, followed by Fisher's exact test. Significance was set at P < 0.05 for all tests.
Results
Body weights in Ahr
+/+ , Ahr +/À and Ahr À/À TRAMP mice TRAMP mice of each Ahr genotype gained weight throughout the 210-day study (results not shown). There were no AhR-dependent alterations in body weights at any age.
Macroscopic prostate tumor incidence in Ahr +/+ , Ahr +/À and Ahr À/À TRAMP mice TRAMP mice were examined at 35-day intervals from 35 to 210 days of age to determine the effect of Ahr genotype on the incidence of macroscopic prostate tumors ( Figure 1 (Figure 2A) . Abundant large T antigen localization was also observed in small nodules, large tumors, and lymph node metastases (results not shown). Localization was similar in prostates of all Ahr genotypes at all stages of tumor development. Also, quantitative analysis of SV40 large T antigen mRNA abundance by RT-PCR did not indicate greater expression in dorsolateral prostates of Ahr +/À and Ahr À/À TRAMP mice compared with Ahr +/+ TRAMP mice at any age ( Figure 2B ). Taken together, these findings demonstrate that loss of AhR in Ahr +/À and Ahr À/À TRAMP mice did not exacerbate prostatic SV40 large T antigen expression, or subsequent development of epithelial hyperplasia. Rather, it appears that greater prostate tumor incidence in mice lacking one or more Ahr allele is independent of these processes.
Chromogranin A and neuropilin-1 mRNA expression: markers of neuroendocrine differentiation in prostate tumors To further characterize the prostate tumors in Ahr +/+ , Ahr
and Ahr À/À C57BL/6J TRAMP mice, we utilized real-time RT-PCR to quantitatively analyze mRNA expression of two genes indicative of neuroendocrine differentiation, chromogranin A and neuropilin-1, at 35-day intervals. Tumor-free ventral prostates had low chromogranin A mRNA expression at all ages investigated ( Figure 3A ). Chromogranin Changes in neuropilin-1 mRNA expression were similar to those observed for chromogranin A. Ventral prostates without tumors had low neuropilin-1 expression at all ages investigated ( Figure 3B ). When no tumors were present, neuropilin-1 expression was not altered between 35 Figure 4A shows hematoxylin and eosin staining of a representative prostate section with diffuse hyperplasia. In the same tissue, chromogranin A immunostaining was not detected ( Figure 4B ). Chromogranin A positive cells were only rarely detected in prostates without tumors, regardless of Ahr genotype. Figure 4C shows a representative macroscopic prostate tumor with predominant absence of glandular structure and only a few glands maintaining glandular structure (arrows). Abundant chromogranin A staining was observed throughout the prostate tumor ( Figure 4D , arrow heads). However, no staining was observed in tumor-free regions retaining glandular architecture (arrows). Chromogranin A staining was reflective of tumor morphology and independent of both mouse age and Ahr genotype, as abundant staining was present in all Ahr +/+ , Ahr +/À and Ahr À/À C57BL/6J TRAMP mouse prostate tumors.
As observed for chromogranin A, immunohistochemical localization of neuropilin-1 was also detected in prostate tumors but not tumor-free prostates (results not shown). Thus, increased expression of neuroendocrine markers is confined to prostate tumors. This suggests that the Ahr regulates onset of neuroendocrine tumors in C57BL/6J TRAMP mice. Figure  5B ). However, similar to effects seen at the mRNA level, AR protein levels were significantly reduced in prostate tumors compared with tumor-free dorsolateral prostates in mice of each Ahr genotype. 
Quantitation of AR mRNA and protein expression
Lymph node metastasis in Ahr
Discussion
The major finding of the present study was that malignant prostate tumors rarely develop in Ahr +/+ TRAMP on a C57BL/6J background, but the incidence is greatly increased in Ahr +/À and Ahr À/À TRAMP mice. As mice age, all prostates developed diffuse hyperplasia characteristic of the TRAMP model, but Ahr +/À and Ahr À/À TRAMP mice develop malignant prostate tumors more frequently than Ahr +/+ mice (Ahr À/À > Ahr +/À > Ahr +/+ ). Evidence suggests that tumors have undergone neuroendocrine differentiation, a key aspect regulated by the Ahr.
The relatively low incidence of prostate tumors in wild-type (Ahr +/+ ) control mice at all ages investigated was below the incidence previously reported in TRAMP studies (21) (22) (23) . TRAMP mice for chemoprevention studies typically cross C57BL/6J with FVB mice, greatly increasing tumor incidence. This raised the question of whether the Ahr would also inhibit prostate carcinogenesis in TRAMP mice of this genetic background. In C57BL/6J · FVB TRAMP mice, greater tumor incidence was observed in Ahr +/À (67%) mice compared with Ahr +/+ (42%) mice (W.A. Fritz, T.-M. Lin, S. Safe, R.W. Moore and R.E. Peterson, unpublished results). Unfortunately, Ahr À/À mice expected to have the greatest tumor incidence were not investigated as they were only available on a C57BL/6J background.
Regardless, these results demonstrate that the Ahr also protects against prostate carcinogenesis in TRAMP mice on the more traditional genetic background (FVB · C57BL/6J) and is not a unique phenomenon in C57BL/6J TRAMP mice.
In the TRAMP model, prostate-specific transgene expression abrogates p53 and retinoblastoma protein (pRb) function, resulting in greater epithelial cell proliferation leading to prostate carcinogenesis. Despite the lower incidence of prostate tumors in Ahr +/+ C57BL/6J TRAMP mice, SV40 large T antigen mRNA abundance was not altered at any time investigated, and all mice expressed SV40 large T antigen protein in the prostate epithelium regardless of Ahr genotype. The mechanism through which the AhR inhibits the process of prostate carcinogenesis remains to be determined. Previous studies suggest that interaction between the AhR and pRb could inhibit SV40 T antigen-mediated reversal of cell cycle arrest (28) . Thus, one plausible mechanism by which the AhR could inhibit prostate carcinogenesis in TRAMP mice is through direct interaction with pRb, thereby inhibiting transgene-induced circumvention of cell cycle arrest. However, interaction with pRb occurs preferentially when the AhR is ligand-bound (29) . Thus, ligand exposure and subsequent nuclear translocation would be required for the AhR to inhibit cell cycle arrest through this mechanism. Furthermore, the AhR also reduced p53 transcriptional activity in human keratinocytes (30) . If the AhR It has previously been demonstrated that the AhR is present in the stroma and epithelium of benign and malignant prostates (17) . This suggests that the AhR could conceivably alter tumorigenesis in the TRAMP model through direct signaling regulation within the epithelium, or by indirect regulation of epithelial growth mediated by the stroma. However, it remains to be demonstrated if stromal or epithelial AhR are required for inhibition of prostate tumorigenesis, or if localization to both cell populations is essential.
Inactivation of AhR signaling in Ahr À/À mouse prostates was confirmed by demonstrating that they were no longer susceptible to ventral prostate agenesis and reduced dorsolateral prostate weights following TCDD exposure (6) . However, there is limited evidence that could account for morphological alterations observed in untreated Ahr À/À mouse prostates (6) . It was noted that macroscopic tumors in our TRAMP mice developed a neuroendocrine phenotype, and it is likely that this process was what was regulated by the AhR. Neuroendocrine differentiation has been previously identified in TRAMP mice (24) and other transgenic mouse models of prostate cancer (31) , and it is believed that rapid onset of neuroendocrine tumors occurs in an androgeninsensitive stem cell population (32) . This possibility is consistent with our observation that AR mRNA and protein expression were significantly reduced in the prostate tumors from each Ahr genotype. Although tumors develop from stem cells following androgen deprivation, it is uncertain how this process would selectively occur in Ahr À/À TRAMP mice that have not been castrated. Future studies will be carried out to identify the mechanisms responsible for AhR-mediated regulation of neuroendocrine differentiation in the prostate as a whole, or selectively in specific stem cell populations in TRAMP mice.
The rapid growth of prostate tumors that have undergone neuroendocrine differentiation is believed to result from loss of androgen sensitivity coupled with production of growth factors that facilitate angiogenesis (33, 34 ). An early angiogenic switch has been described in TRAMP mouse prostates as HIF-1a levels are elevated in hyperplastic lesions prior to tumor growth (25) . Sufficient elevation of HIF-1a would presumably allow greater interaction with the dimerization partner, HIF-1b, otherwise known as ARNT, leading to greater VEGF production. Interestingly, ARNT is also a dimerization partner for the AhR (35) , suggesting that competition for the same dimerization partner in mice expressing the AhR would reduce HIF-1a signaling. In this case, a greater proportion of ARNT would interact with the AhR, and would be less likely to dimerize with accumulating HIF-1a, thereby reducing VEGF production and subsequent angiogenesis necessary to support prostate tumor growth. A similar phenomenon mediates cardiac hypertrophy in AhR null mice (36) , where greater HIF-1a levels were associated with a subsequent increase in VEGF mRNA abundance. However, total HIF-1a protein levels did not differ in 105 or Figure 1 . Ã Significantly different from Ahr +/+ TRAMP mice at the same age (P < 0.05). 140-day-old Ahr +/+ , Ahr +/À , or Ahr À/À TRAMP prostates without tumors, even though HIF-1a activity, characterized by VEGF production, increased between these ages (W.A. Fritz, T.-M. Lin and R.E. Peterson, unpublished results). Despite similar HIF-1a protein levels at an age when tumors are becoming more frequent, it is possible that Ahr À/À TRAMP mouse prostates are more susceptible to increasing HIF-1a activity than Ahr +/+ TRAMP prostates, resulting in greater VEGF production that facilitates progression from proliferative lesions to larger tumors. However, this possible mechanism remains to be demonstrated.
In addition to cardiac hypertrophy, AhR null mice exhibit reduced liver weights (13) associated with altered vascular development due to a patent ductus venosus (37) , whereby closure of the portocaval shunt during early postnatal life fails to occur. AhR null mice also exhibit impaired immune development, evidenced by reduced lymphocyte accumulation in the spleen and lymph nodes (13) . While it is uncertain how smaller livers could be causally associated with greater propensity for prostate carcinogenesis, heightened immune responses may be associated with prostate carcinogenesis (38) . Because inflammatory cells commonly identified in the prostate produce oxidants capable of initiating cellular and genomic damage (39) , it is unlikely that greater prostate tumor development would occur through this mechanism in AhR null mice, which would presumably have diminished immunity, rather than a heightened immune response. However, prostate-specific effects on immune responses remain to be investigated in AhR null TRAMP mice.
Alternatively, the AhR may affect prostate carcinogenesis through cross-talk with other signaling pathways, including the androgen signaling cascade (40) . While castration (41) and anti-androgen (42) administration effectively reduce prostate carcinogenesis in TRAMP mice, it is unlikely that the AhR protects in this manner as circulating androgens are unaltered and androgen-dependent gene expression is maintained in AhR null mice (6). However, it remains possible that subtle perturbation of androgen signaling could have pronounced effects on prostate cancer given sufficient time to exert an effect. The AhR also can interact with estrogen receptors through cross-talk mechanisms (43, 44) . Although estrogenic/antiestrogenic compounds effectively inhibit prostate carcinogenesis in TRAMP mice (45, 46) , regulation of estrogen signaling by the AhR that would confer protection have yet to be identified in the TRAMP prostate.
In conclusion, using C57BL/6J TRAMP mice not treated with TCDD, we demonstrate that absence of AhR signaling in Ahr À/À mice results in greater prostate tumor incidence and that Ahr +/+ mice rarely develop prostate tumors. We have shown that tumors forming in our TRAMP mice from all Ahr genotypes are neuroendocrine in nature. This inhibition of prostate tumor formation by the AhR would seem to contradict the association between AhR activation by TCDD and greater risk of prostate cancer in humans and induction of pre-cancerous lesions in mice exposed to TCDD (18, 20) . Yet, this reflects the seemingly contradictory effects observed in developing prostates, whereby both activation of AhR signaling by TCDD and absence of the AhR in Ahr À/À mice resulted in reduced dorsolateral and anterior prostate weights (6) . Thus, the physiological role of the AhR appears to reflect an intricate balance where baseline signaling is required for normal prostate development, but greater activation of the AhR by potent ligands, particularly TCDD, disrupts normal prostate development and may increase prostate cancer risk. Future studies will investigate the mechanisms through which the AhR regulates prostatic carcinogenesis, and how the AhR inhibits onset of neuroendocrine prostate tumors.
